Kochi: In an important step that will allow Indian doctors access to the best of global healthcare knowledge and expertise, Kochi based Aster Medcity has inked a MoU with the Thomas Jefferson University (TJU), an iconic American institution with a rich tradition dating back to 1824.
The MoU embraces a range of collaborative processes opening up tremendous opportunity to equip healthcare professionals through learning, research and imbibing best global practices for the benefit of the patients. Aster Medcity and the Thomas Jefferson University will initiate this relationship with the Multi-Organ Transplant programme.
Dr. Azad Moopen, CMD, Aster DM Healthcare said, “The Aster Multi-Organ Transplant programme has already made a mark in a short period since the first liver transplant at Aster Medcity in November 2015. We now embark upon an exciting new stage of our journey with this collaboration with the Thomas Jefferson University. We look forward to our partnership adding a new dimension to Aster Multi-Organ Transplant programme with access to global best practices in the field of organ transplants enhancing the quality of care.”
The Thomas Jefferson University is the largest free-standing health sciences university in Philadelphia with the flagship Sidney Kimmel Medical College known as one of the largest private medical colleges in USA.
Dr. Cataldo Doria, Director, Jefferson Transplant Institute said, “We are glad to have this opportunity to associate with one of India’s premiere healthcare institutions. In a short time, Aster Medcity has shown its expertise in multi-organ transplant. We look forward to interacting and collaborating with Aster’s team of transplant surgeons who have performed landmark surgeries in their careers including the first split liver transplant, first simultaneous pancreas kidney transplant and first simultaneous liver kidney transplant.”
The MOU will also extend to other areas including Knowledge Transfer through organising symposia, conferences and short courses; Training and Education through Institutional exchange programs, joint study groups and joint publications; Validation of protocols used in treatment regimens including various parameters like diagnosis, treatment and support infrastructure; and Clinical Research.
“The signing of this MOU will facilitate bi directional learning with joint collaborative models that will benefit patient communities in both the countries”, said Dr. Harish Pillai, CEO, Aster Medcity.
Kerala Biz News